Sam, a 25-year-old male, is brought in to the hospital by the police due to public concern regarding some bizarre and distressed behaviour in the city centre. The police say Sam will only speak of being “scared of them”. He’s currently curled up in a ball, in the corner of the room.
Mental health act
Section 136 allows police to bring a person from a public place to a place of safety.
The place of safety can be A&E, a police station or a specific ‘136 Suite’.
A person can be held under Section 136 for a maximum of 72 hours.
During this time an assessment of the individual should take place by a mental health professional.
If a person:
has/is deemed to have a mental disorder which requires assessment or treatment
is suffering from a sufficiently serious disorder that means admission is necessary for the health and safety of the patient or the public
requires hospital admission for assessment/treatment
is unable and/or unwilling to agree to hospital admission
Two registered medical practitioners (one of which must be Section 12 approved) and an approved mental health professional (AMHP – usually a social worker) submit reports which support that the case satisfies the above criteria.
“They’re after me…they’re going to get me. I’ve heard them talking about me.”
“They know what I’m doing, they know where I am. They follow me everywhere. They put a tracker in my head while I was asleep a year ago. Now they know where I am and what I think.”
“They know what I’m thinking, and they make me think about hurting my family. I don’t want to hurt my family, but I keep getting these thoughts…it’s getting worse.”
“The chip was put in my brain last year. They’ve been getting louder ever since.”
It is not possible to obtain any more history from Sam.
Collateral history (e.g. friends, partners, family)
GP records (including past medical history and regular medications)
Police records (previous episodes)
Drug screening (urine & blood) – e.g. cannabis, amphetamines, LSD, cocaine
FBC – white cells/infection markers
U&Es – electrolyte disturbances may indicate an underlying medical cause
CT/MRI head – to rule out organic causes (e.g. encephalitis, space-occupying lesion)
EEG -if seizure activity suspected
The story continues…
You return to Sam to discuss the need for blood tests and find a lady sat with him. Jane introduces herself as Sam’s mother and explains that Sam usually lives with her. She explains that Sam is known to have schizophrenia. This was diagnosed during university and has been somewhat turbulently managed since. He has been on several different antipsychotic medications in the past 4 years, none of which have seemed to control the symptoms. Sam has not been able to find a job since university and has few friends. There is no known illicit drug use and he has no other past medical history.
Sam has a history demonstrating schizophrenia that has not responded to first-line treatments (treatment-resistant schizophrenia). Clozapine is indicated for treatment-resistant schizophrenia, specifically when the illness has been unresponsive to at least2antipsychotic medications (at least one of which is an atypical antipsychotic).
Baseline blood tests – FBC (clozapine can potentially cause fatal agranulocytosis)
Cardiovascular risk assessment (BMI, fasting lipids) – clozapine increases the risk of cardiovascular disease, including myocarditis
Fasting blood glucose or HbA1c – clozapine is associated with an increased risk of diabetes
Baseline vital signs – clozapine can cause postural hypotension (so if a patient already had low blood pressure or issues with postural hypotension, it may not be appropriate)
ECG – to establish a baseline – clozapine is associated with an increased risk of cardiovascular disease
Often initiated during an inpatient stay, commencing at a low dose and then slowly titrated upwards.
Plasma clozapine levels should be measured after the initial target dose is reached (approximately 2 weeks).
Blood pressure should be monitored regularly, as postural hypotension can occur.
For the first month patients on clozapine should have the following monitored:
Vital signs (e.g. fever in agranulocytosis or postural hypotension)
ECG (monitoring for acute changes such as those seen in myocarditis or myocardial infarction)
CRP (useful if considering infection in the context of agranulocytosis)
Troponin levels (raised in myocarditis and myocardial infarction)
During the first 6 months of treatment, WCC should be measured weekly, then fortnightly.
1 in 1000 people on treatment develop agranulocytosis, and this usually in the first 6 months of treatment.
Clozapine should be temporarily stopped or discontinued if agranulocytosis develops.
Weight gain and impaired glucose tolerance
Weight should be monitored regularly as weight gain is likely to occur in patients taking clozapine.
Insulin-resistance may also develop, so HbA1c should be monitored every 6 months.
1. Royal College of Psychiatrists. Being sectioned. Available from: [LINK]
2. UK Government. Mental Health Act of 1983. Available from: [LINK]
3. Dr Roger Henderson. Schizophrenia. Updated May 2016. Available from: [LINK]
4. NICE. Psychosis and schizophrenia in adults. Published February 2014. Available from: [LINK]